3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colonic Neoplasms
8
Carcinoma, Hepatocellular
8
Stomach Neoplasms
7
Colorectal Neoplasms
7
Pancreatic Neoplasms
5
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Cyst
2
Pain, Postoperative
2
Esophageal Squamous Cell Carcinoma
2
Visceral Pain
1
Surgical Wound Infection
1
Sigmoid Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pain
1
Nutrition Disorders
1
Lung Injury
1
Liver Neoplasms
1
Klatskin Tumor
1
Intestinal Perforation
1
Insulin Resistance
1
Infections
1
Gastroparesis
1
Feeding and Eating Disorders
1
Esophageal Neoplasms
1
Dumping Syndrome
1
Diverticulosis, Colonic
1
Cholangitis
1
Biliary Tract Neoplasms
1
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
17
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Drug Therapy
9
Biopsy
9
Taxes
8
Folfox protocol
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
Endoscopy
7
tremelimumab
6
Specimen Handling
6
Endoscopy, Digestive System
6
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
Saline Solution
×
Gastrointestinal
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled